A fixed-dose combination topical preparation containing a potent corticosteroid (Betamethasone), an aminoglycoside antibiotic (Gentamicin), and an imidazole antifungal (Miconazole). It is designed for the treatment of inflammatory dermatoses complicated by or at high risk of bacterial and fungal infections, commonly seen in tropical climates like India. It provides anti-inflammatory, antipruritic, antibacterial, and antifungal actions in a single formulation.
Adult: Apply a thin film to the affected area 2-3 times daily, or as directed by the physician. Duration should be limited, usually 1-2 weeks, and not exceeding 4 weeks.
Note: Wash and dry the affected area thoroughly. Apply a thin layer and rub gently. Wash hands after application unless hands are the treated area. Do not cover with occlusive dressings unless specifically advised. Do not use in or near the eyes.
The combination exerts a multi-pronged therapeutic effect. Betamethasone suppresses inflammation and immune response. Gentamicin provides bactericidal action against common skin pathogens. Miconazole inhibits fungal growth and has some Gram-positive antibacterial activity.
Pregnancy: Category C (US FDA). Topical corticosteroids, especially potent ones, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Avoid large amounts or long-term use. Gentamicin is Category D for systemic use but risk from topical use is negligible unless applied extensively.
Driving: No known effects on driving ability.
| Other Topical Corticosteroids | Additive risk of local and systemic side effects. | Major |
| Systemic Aminoglycosides (e.g., Amikacin, Streptomycin) | Increased risk of ototoxicity and nephrotoxicity if significant topical gentamicin is absorbed. | Moderate |
| Warfarin and other Coumarin Anticoagulants | Miconazole (systemic) can potentiate anticoagulant effect. Significance with topical use is low but caution advised. | Moderate |
| Oral Hypoglycemic Agents (Sulfonylureas) | Miconazole may potentiate hypoglycemic effect. Topical significance is minimal. | Minor |
Same composition (Betamethasone (0.05% w/w) + Gentamicin (0.1% w/w) + Miconazole (2% w/w)), different brands: